Results 131 to 140 of about 14,491 (226)

Comparison of the efficacy based on clinicopathological characteristics and the safety of first-line treatments for patients with advanced ALK rearrangement non-small cell lung cancer: a network meta-analysis. [PDF]

Front Oncol
Li Y, Wen Y, Zhang W, Zhao Y, Zhou L, Zeng X, Kang X, Li L.   +7 more
europepmc   +1 more source

Pooled systemic efficacy and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer [PDF]

, 2017
et al,, Govindan, Ramaswamy
core   +1 more source

Effects of 31 FDA approved small-molecule kinase inhibitors on isolated rat liver mitochondria [PDF]

, 2016
Alec Salminen, James Greenhaw, Jun Zhang, Lijun Ren, Matthew Bryant, Matthew White, Qiang Shi, Qiangen Wu, Thomas Papoian, William Mattes, William Salminen, Xi Yang, Yong Luo   +12 more
core   +1 more source

Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report. [PDF]

Lung Cancer (Auckl)
Lee ATM, Park CJ, Arter ZL, Nagasaka M, Ou SI.   +4 more
europepmc   +1 more source

Malignant Tumor (4) Molecular Targeted Drugs [PDF]

, 2018
丸 義朗, 塚原 富士子
core   +2 more sources

Insights into brain metastasis in patients with + lung cancer: is the brain truly a sanctuary? [PDF]

core   +1 more source

Real-world first-line outcomes of alectinib and brigatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: a nationwide South Korean cohort study using the health insurance review and assessment data. [PDF]

Transl Lung Cancer Res
Kim HJ, Lee EA, Park JH, Lee HW.
europepmc   +1 more source

Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study. [PDF]

Transl Lung Cancer Res
Zhang H, Wu Z, Lu T, Zhang H, Li J, Zhang D, Yu S, Guo X, Feng X, Liu J, Shi Y, Gao X, Liu X, Chen M, Zhao J, Zhong W, Hu Y, Xu Y, Wang M.   +18 more
europepmc   +1 more source

Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial. [PDF]

Future Oncol
Ahn MJ, Delmonte A, Ghosh S, Hochmair M, Yang TY, Yang JC, Han JY, Hansen KH, Wu Y, Wan Y, Lin HM, Kretz J, Hupf B, Kurec AM, Churchill EN, Fram RJ, Cabasag CJ, Goriya V, Zhao Y, Campelo MRG.   +19 more
europepmc   +1 more source

Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study [PDF]

, 2022
Ahn, Mj, Barlesi, F, Bearz, A, de Marinis, F, Felip, E, Garrido, P, Ignatius Ou SH,, Kim, Dw, Kim, Es., Kim, Sw, Lin, Hm, Liu, G, Mazieres, J, Migliorino, Mr, Mok, T, Morabito, A, Nishio, M, Niu, H, Novello, S, Pérol, M, Yang, H, Zhang, P, Zhou, C   +22 more
core   +1 more source